Liu Tengfei, Huang Gan, Guo Xin, Ji Qiuran, Yu Lu, Zong Runzhe, Li Yiquan, Song Xiaomeng, Fu Qingyi, Xue Qidi, Zheng Yi, Zeng Fanshuo, Sun Ru, Chen Lin, Gao Chengjiang, Liu Huiqing
Department of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan 250012, China.
Key Laboratory of Infection and Immunity of Shandong Province & Department of Immunology, School of Basic Medical Sciences, Shandong University, Jinan 250012, China.
Acta Pharm Sin B. 2025 Aug;15(8):4014-4029. doi: 10.1016/j.apsb.2025.06.005. Epub 2025 Jun 9.
Receptor-interacting protein kinase 1 (RIPK1) plays an essential role in regulating the necroptosis and apoptosis in cerebral ischemia-reperfusion (I/R) injury. However, the regulation of RIPK1 kinase activity after cerebral I/R injury remains largely unknown. In this study, we found the downregulation of protein arginine methyltransferase 1 (PRMT1) was induced by cerebral I/R injury, which negatively correlated with the activation of RIPK1. Mechanistically, we proved that PRMT1 directly interacted with RIPK1 and catalyzed its asymmetric dimethylarginine, which then blocked RIPK1 homodimerization and suppressed its kinase activity. Moreover, pharmacological inhibition or genetic ablation of PRMT1 aggravated I/R injury by promoting RIPK1-mediated necroptosis and apoptosis, while PRMT1 overexpression protected against I/R injury by suppressing RIPK1 activation. Our findings revealed the molecular regulation of RIPK1 activation and demonstrated PRMT1 would be a potential therapeutic target for the treatment of ischemic stroke.
Proc Natl Acad Sci U S A. 2025-6-17
Biochem Pharmacol. 2025-6-23
Mol Neurobiol. 2024-7
Signal Transduct Target Ther. 2022-7-6
Nat Commun. 2021-10-22